JAMA Medical News

New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions

22 min · 18 de jun de 2026
Portada del episodio New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions

Descripción

Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more. Related Content: * A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026 [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7591?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links]

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de JAMA Medical News!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

291 episodios